SoquinololAlternative Names: WE 704
Latest Information Update: 24 Jan 2013
At a glance
- Originator Unknown
- Developer AbbVie
- Class Heart failure therapies
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 01 Aug 1997 Discontinued-preregistration for Heart failure (Unknown route)